Commence Bio is an intriguing company that has recently entered the mesenchymal stem cell (MSC) marketplace. Commence Bio came across my radar screen earlier this year right around the time that it announced the name change, as highlighted in the company press release below.
Specifically, Commence Bio is a pre-clinical stage biotechnology company that was “founded on the vision that cancer and inflammatory diseases can be optimally treated by rebooting patients’ immune systems with a new class of medicinal stem cells: MSC1 & MSC2.” The company is now developing a therapeutic pipeline, as well as offering research products (MSC1 and MSC2 cells and media). The concept around which the company is based is that its proprietary technology programs naïve MSCs so that they can localize to sites of immune dysfunction.
